Research programme: botulinum toxin vaccine - Soligenix

Drug Profile

Research programme: botulinum toxin vaccine - Soligenix

Alternative Names: BT-VACC

Latest Information Update: 05 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thomas Jefferson University
  • Developer Soligenix
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Botulism

Most Recent Events

  • 28 Aug 2007 This vaccine is still in active development
  • 11 Apr 2006 Preclinical data have been added to the Viral infections immunogenicity section
  • 14 May 2003 Preclinical trials in Botulism in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top